Relevant to the diabetes research field, activation of the alternative pathway of complement leads to C3 cleavage and release of the bioactive peptide C3a, which augments glucose-stimulated insulin secretion from beta-cells via stimulation of the C3a receptor (C3aR) [[13], [14], [15]]. The gene discussed is INS; the disease is diabetes mellitus.